Once people don’t have justifiable access to medicine, the disease will stay longer with those people. Some will end up dying ...

Dr. Lukulay joined Bio Usawa as Chief Regulatory Officer in 2024, and has been pivotal in advancing the company's programs ...

MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the ...

Stem cell research and regenerative medicine are growing markets in the life science sector, and the top stem cell companies ...

OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the fourth ...

Pfizer made changes to its DEI webpage, joining other companies across different industries repositioning their messaging ...

Pfizer (NYSE:PFE) and GSK (NYSE:GSK) revamp DEI initiatives, emphasizing merit-based diversity amid changing U.S. policies.

The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...

Shares of Pfizer Inc. PFE advanced 1.26% to $26.43 Friday, on what proved to be an all-around favorable trading session for ...

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Pfizer (PFE – Research Report). The company’s shares closed ...

For businesses at the center of these shifts in regulatory sentiment, the volatility behind the regulation is often more ...